Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
IRCCS San Raffaele
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Established diagnosis of UC according to the current ECCO Guidelines;
2. Age ≥18 years old;
3. Patients must have received mirikizumab as UC treatment, as per clinical practice;
4. At least 12 weeks follow-up visits after baseline;
You may not be if
1. Diagnosis of undetermined IBD, CD or other gastrointestinal inflammatory conditions;
2. Age \< 18 years-old;
3. Acute severe IBD complications necessitating hospitalization at baseline;
Clareo Health | Effectiveness and Safety of Mirikizumab in Patients With Moderate-to-severe Ulcerative Colitis: a Real-life Retrospective Multicenter Study
